Ganoderic acid A exerted antidepressant-like action through FXR modulated NLRP3 inflammasome and synaptic activity

• Published in: Biochemical pharmacology 2021-06, Vol.188, p.114561-114561, Article 114561
• Main Authors: Bao, Hongkun, Li, Haoran, Jia, Yue, Xiao, Yuhuan, Luo, Shaolei, Zhang, Dandan, Han, Li, Dai, Lili, Xiao, Chunjie, Feng, Lei, Feng, Yuan, Yang, Yang, Wang, Han, Wang, Gang, Du, Jing
• Format: Article
• Language: English
• Subjects: AMPA receptor; Farnesoid X receptor; Ganoderic acid A; Major depressive disorder; NLRP3 inflammasome
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2021.114561

[Display omitted] Major depressive disorder (MDD) is a common, chronic, recurrent disease. The existing drugs are ineffective for approximately half of patients, so the development of antidepressant drugs with novel mechanisms is urgent. Cumulative evidence has shown neuro-inflammation plays a key role in the etiology of major depressive disorder. Clinical studies implicated that bile acids, an important component of gut-brain axis, inhibit neuro-inflammation and mediate the pathophysiology of the MDD. Here, we found that ganoderic acid A (GAA) modulated bile acid receptor FXR (farnesoid X receptor), inhibited brain inflammatory activity, and showed antidepressant effects in the chronic social defeat stress depression model, tail suspension, forced swimming, and sucrose preference tests. GAA directly inhibited the activity of the NLRP3 inflammasome, and activated the phosphorylation and expression of the AMPA receptor by modulating FXR in the prefrontal cortex of mice. If we knocked out FXR or injected the FXR-specific inhibitor z-gugglesterone (GS), the antidepressant effects induced by GAA were completely abolished. These results suggest that GAA modulates the bile acid receptor FXR and subsequently regulates neuroimmune and antidepressant behaviors. GAA and its receptor FXR have potential as targets for the treatment of MDD.